A new case has brought into the spotlight the risks responding parties face when entering into ESI protocols with detailed disclosure obligations regarding technology-assisted review (TAR). In In re Valsartan, Losartan, and Irbesartan Products Liability Litigation (D.N.J. Dec. 2, 2020), the court refused to approve a responding party's proposed TAR process and insisted that the design and execution of a TAR workflow required "an unprecedented degree of transparency" between the responding and requesting parties.